Fabry Disease Market: Global Analysis and Opportunity and Forecast by 2024: AbbVie, Pfizer, Shire, Green Cross
Fabry Disease is an X-linked genetic disease caused by a deficiency of the enzyme ?galactosidase A (?-Gal A) in the body. The enzyme ?-Gal A's function is to break down fatty element called globotriaosylceramide (or GL3). When ?-Gal A is absent, GL3 builds up in the blood vessel walls in the body.
View full press release